---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003879"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:30:10.173384+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma expects 2023 Portfolio Receipts of ~$3.05B, exceeding upper guidance; 11% underlying growth

## Summary
- Portfolio Receipts for FY2023 expected ~$3.05B, above prior guidance of $2.95B-$3.0B; underlying growth 11% YoY.
- Net cash from operations for FY2023 ~$2.98B-$2.99B.
- Announced transactions since 2020 total ~$13B, including $4.0B in 2023; synthetic royalty transactions at record $775M.
- Capital deployment target of $10B-$12B from 2022-2026; longer-term potential to double annual deployment to $4B-$5B.
- Portfolio investments since 2020 expected to add ~$1.2B to Portfolio Receipts in 2025 based on consensus sales forecasts.

## SEC filing metadata
- accession: 0001193125-24-003879
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312524003879/0001193125-24-003879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312524003879/d910834d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003879
- JSON: https://secwatch.observer/filing/0001193125-24-003879.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003879.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.